Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss) Gain	Accumulated Deficit
Balances, at Beginning of period at Dec. 31, 2022	$ 197,546	$ 3	$ 408,333	$ (1,813)	$ (208,977)
Balances, at Beginning of period (in shares) at Dec. 31, 2022		40,287,097
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under equity private placement, net of issuance costs of $264	129,736	$ 1	129,735
Issuance of shares under equity private placement, net of issuance costs of $264 (in shares)		13,211,381
Stock-based compensation expense	16,804		16,804
Employee stock purchase plan expense	452		452
Exercise of stock options	2,722		2,722
Exercise of stock options (in shares)		733,867
Issuance of shares under employee stock purchase plan	1,050		1,050
Issuance of shares under employee stock purchase plan (in shares)		333,503
Vesting of early exercised stock options	$ 80		80
Vesting of early exercised stock options (in shares)	2,329,483	18,640
Vesting of restricted stock awards (in shares)		191,296
Vesting of performance-based restricted stock unit awards (in shares)		217,000
Net unrealized gain (loss) on marketable securities	$ 2,160			2,160
Net Income (Loss)	(96,655)				(96,655)
Balances, at End of period at Dec. 31, 2023	253,895	$ 4	559,176	347	(305,632)
Balances, at End of period (in shares) at Dec. 31, 2023		54,992,784
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	22,009		22,009
Employee stock purchase plan expense	573		573
Issuance of shares and pre-funded warrants under equity private placement, net of issuance costs of $12,998	237,001	$ 2	236,999
Issuance of shares and pre-funded warrants under equity private placement, net of issuance costs of $12,998 (in shares)		19,928,875
Issuance of shares under at-the-market offering, net of issuance costs of $166	22,787		22,787
Issuance of shares under at-the-market offering, net of issuance costs of $166 (in shares)		1,772,278
Exchange of common stock shares for pre-funded warrants (in shares)		(3,420,000)
Exercise of stock options	$ 1,518		1,518
Exercise of stock options (in shares)	460,744	430,159
Issuance of shares under employee stock purchase plan	$ 859		859
Issuance of shares under employee stock purchase plan (in shares)		112,853
Vesting of early exercised stock options (in shares)	2,213,715
Vesting of restricted stock awards (in shares)		92,659
Vesting of performance-based restricted stock unit awards (in shares)		403,000
Net unrealized gain (loss) on marketable securities	$ (204)			(204)
Net Income (Loss)	(129,474)				(129,474)
Balances, at End of period at Dec. 31, 2024	$ 408,964	$ 6	$ 843,921	$ 143	$ (435,106)
Balances, at End of period (in shares) at Dec. 31, 2024		74,312,608